Literature DB >> 1706616

Identification of autophosphorylation sites of HER2/neu.

R Hazan1, B Margolis, M Dombalagian, A Ullrich, A Zilberstein, J Schlessinger.   

Abstract

HER2 or c-erbB-2 is a putative growth factor receptor with sequence homology to the epidermal growth factor receptor. It is the human homologue of the rat protooncogene neu and may have an important role in human malignancies such as breast and ovarian cancers. Like other growth factor receptors, HER2 has intrinsic protein tyrosine kinase activity and undergoes autophosphorylation. Recently, we have demonstrated that, similar to the epidermal growth factor receptor, all autophosphorylation sites of HER2 are localized in the carboxyl terminus of this protein. In the present study, immunopurified HER2 was allowed to autophosphorylate, and tryptic phosphopeptides were generated. After purification of these phosphopeptides by high performance liquid chromatography, microsequencing was performed. Utilizing this approach, two autophosphorylation sites were unequivocally identified at Y1023 and Y1248. The sequences of two other tyrosine phosphorylated tryptic peptides were determined, but the exact site of autophosphorylation could not be determined because multiple tyrosines were located on each peptide. However, each of these peptides contains tyrosines that correspond to major autophosphorylation sites of the epidermal growth factor receptor, suggesting that, in addition to Y1023 and Y1248, Y1139 and Y1222 also serve as autophosphorylation sites of HER2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706616

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  30 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.

Authors:  Y Mikami; J G Davis; K Dobashi; W C Dougall; J N Myers; V I Brown; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

4.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

5.  Changes in mammary caveolin-1 signaling pathways are associated with breast cancer risk in rats exposed to estradiol in utero or during prepuberty.

Authors:  Ayesha N Shajahan; Shruti Goel; Sonia de Assis; Bin Yu; Robert Clarke; Leena Hilakivi-Clarke
Journal:  Horm Mol Biol Clin Investig       Date:  2010-06

Review 6.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

7.  HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Authors:  Delphine R Boulbes; Stefan T Arold; Gaurav B Chauhan; Korina V Blachno; Nanfu Deng; Wei-Chao Chang; Quanri Jin; Tzu-Hsuan Huang; Jung-Mao Hsu; Samuel W Brady; Chandra Bartholomeusz; John E Ladbury; Steve Stone; Dihua Yu; Mien-Chie Hung; Francisco J Esteva
Journal:  Mol Oncol       Date:  2014-11-11       Impact factor: 6.603

8.  eps15, a novel tyrosine kinase substrate, exhibits transforming activity.

Authors:  F Fazioli; L Minichiello; B Matoskova; W T Wong; P P Di Fiore
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

9.  Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.

Authors:  L Bangalore; A J Tanner; A P Laudano; D F Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion.

Authors:  Jason J Northey; Juliann Chmielecki; Elaine Ngan; Caterina Russo; Matthew G Annis; William J Muller; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.